Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?

Seven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS,...

Full description

Bibliographic Details
Main Authors: Jawad Al-Kassmy, Jannie Pedersen, Gary Kobinger
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/12/8/861
_version_ 1797559667488980992
author Jawad Al-Kassmy
Jannie Pedersen
Gary Kobinger
author_facet Jawad Al-Kassmy
Jannie Pedersen
Gary Kobinger
author_sort Jawad Al-Kassmy
collection DOAJ
description Seven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS, researchers have been trying to draw lessons from previous outbreaks to find a potential cure. Although there were five Phase I human vaccine trials against SARS and MERS, the lack of data in humans provided us with limited benchmarks that could help us design a new vaccine for Coronavirus disease 2019 (COVID-19). In this review, we showcase the similarities in structures of virus components between SARS-CoV, MERS-CoV, and SARS-CoV-2 in areas relevant to vaccine design. Using the ClinicalTrials.gov and World Health Organization (WHO) databases, we shed light on the 16 current approved clinical trials worldwide in search for a COVID-19 vaccine. The different vaccine platforms being tested are Bacillus Calmette–Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors. By thoroughly analyzing different trials and platforms, we also discuss the advantages and disadvantages of using each type of vaccine and how they can contribute to the design of an adequate vaccine for COVID-19. Studying past efforts invested in conducting vaccine trials for MERS and SARS will provide vital insights regarding the best approach to designing an effective vaccine against COVID-19.
first_indexed 2024-03-10T17:48:34Z
format Article
id doaj.art-12d141bb113e46b897aff4a2bc5e8f8a
institution Directory Open Access Journal
issn 1999-4915
language English
last_indexed 2024-03-10T17:48:34Z
publishDate 2020-08-01
publisher MDPI AG
record_format Article
series Viruses
spelling doaj.art-12d141bb113e46b897aff4a2bc5e8f8a2023-11-20T09:26:18ZengMDPI AGViruses1999-49152020-08-0112886110.3390/v12080861Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?Jawad Al-Kassmy0Jannie Pedersen1Gary Kobinger2Department of Experimental Surgery, McGill University, Montreal General Hospital 1650 Cedar Avenue, Montreal, QC H3G 1A4, CanadaAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1V 4G2, CanadaAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1V 4G2, CanadaSeven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS, researchers have been trying to draw lessons from previous outbreaks to find a potential cure. Although there were five Phase I human vaccine trials against SARS and MERS, the lack of data in humans provided us with limited benchmarks that could help us design a new vaccine for Coronavirus disease 2019 (COVID-19). In this review, we showcase the similarities in structures of virus components between SARS-CoV, MERS-CoV, and SARS-CoV-2 in areas relevant to vaccine design. Using the ClinicalTrials.gov and World Health Organization (WHO) databases, we shed light on the 16 current approved clinical trials worldwide in search for a COVID-19 vaccine. The different vaccine platforms being tested are Bacillus Calmette–Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors. By thoroughly analyzing different trials and platforms, we also discuss the advantages and disadvantages of using each type of vaccine and how they can contribute to the design of an adequate vaccine for COVID-19. Studying past efforts invested in conducting vaccine trials for MERS and SARS will provide vital insights regarding the best approach to designing an effective vaccine against COVID-19.https://www.mdpi.com/1999-4915/12/8/861coronavirusCOVID-19MERSSARSvaccineclinical trials
spellingShingle Jawad Al-Kassmy
Jannie Pedersen
Gary Kobinger
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Viruses
coronavirus
COVID-19
MERS
SARS
vaccine
clinical trials
title Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
title_full Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
title_fullStr Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
title_full_unstemmed Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
title_short Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
title_sort vaccine candidates against coronavirus infections where does covid 19 stand
topic coronavirus
COVID-19
MERS
SARS
vaccine
clinical trials
url https://www.mdpi.com/1999-4915/12/8/861
work_keys_str_mv AT jawadalkassmy vaccinecandidatesagainstcoronavirusinfectionswheredoescovid19stand
AT janniepedersen vaccinecandidatesagainstcoronavirusinfectionswheredoescovid19stand
AT garykobinger vaccinecandidatesagainstcoronavirusinfectionswheredoescovid19stand